Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Innoviva, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WALTHAM, MASS.--(BUSINESS WIRE)--INNOVIVA SPECIALTY THERAPEUTICS, A SUBSIDIARY OF INNOVIVA, INC. (NASDAQ: INVA), TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED NUZOLVENCE (ZOLIFLODACIN) FOR ORAL SUSPENSION, A FIRST-IN-CLASS, SINGLE-DOSE ORAL MEDICATION FOR THE TREATMENT OF UNCOMPLICATED UROGENITAL GONORRHEA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WEIGHING AT LEAST 35 KG. THE DEVELOPMENT OF NUZOLVENCE WAS PART OF A PRIVATE, NOT-FOR-PROFIT COLLABORATION.

U.S. FDA APPROVES NUZOLVENCE (ZOLIFLODACIN), A FIRST-IN-CLASS, SINGLE-DOSE, ORAL ANTIBIOTIC FOR THE TREATMENT OF UNCOMPLICATED UROGENITAL GONORRHEA IN ADULTS AND ADOLESCENTS

WALTHAM, MASS.--(BUSINESS WIRE)--INNOVIVA SPECIALTY THERAPEUTICS, INC., A SUBSIDIARY OF INNOVIVA, INC. (NASDAQ: INVA), TODAY ANNOUNCED THE PUBLICATION OF POSITIVE RESULTS FROM A PIVOTAL PHASE 3 TRIAL EVALUATING ITS INVESTIGATIONAL SINGLE-DOSE, ORAL ANTIBIOTIC ZOLIFLODACIN FOR THE TREATMENT OF UNCOMPLICATED UROGENITAL GONORRHEA IN THE LANCET. THE TRIAL WAS SPONSORED AND LED BY THE COMPANY'S NOT-FOR-PROFIT PARTNER, THE GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP (GARDP). GONORRHEA C.

INNOVIVA SPECIALTY THERAPEUTICS ANNOUNCES PUBLICATION IN THE LANCET OF POSITIVE ZOLIFLODACIN PHASE 3 DATA FOR THE TREATMENT OF UNCOMPLICATED UROGENITAL GONORRHEA

BURLINGAME, CALIF.--(BUSINESS WIRE)--INNOVIVA, INC. (NASDAQ: INVA) (INNOVIVA OR THE COMPANY), A DIVERSIFIED HOLDING COMPANY WITH A CORE ROYALTIES PORTFOLIO, A LEADING CRITICAL CARE AND INFECTIOUS DISEASE PLATFORM KNOWN AS INNOVIVA SPECIALTY THERAPEUTICS (IST), AND A PORTFOLIO OF STRATEGIC INVESTMENTS IN HEALTHCARE ASSETS, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 37TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE IN NEW YORK, NY ON TUESDAY, DECEMBER 2, 2025 A.

INNOVIVA TO PARTICIPATE IN THE 37TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE

BURLINGAME, CALIF.--(BUSINESS WIRE)--INNOVIVA, INC. (NASDAQ: INVA) (INNOVIVA OR THE COMPANY), A DIVERSIFIED HOLDING COMPANY WITH A CORE ROYALTIES PORTFOLIO, A LEADING CRITICAL CARE AND INFECTIOUS DISEASE PLATFORM KNOWN AS INNOVIVA SPECIALTY THERAPEUTICS (IST), AND A PORTFOLIO OF STRATEGIC INVESTMENTS IN HEALTHCARE ASSETS, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND HIGHLIGHTED SELECT CORPORATE PROGRESS AND ACHIEVEMENTS. INNOVIVA DELIVERED STRONG T.

INNOVIVA REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS; HIGHLIGHTS RECENT COMPANY PROGRESS

D'ESPARBES TO LEAD ANTHEIA'S FINANCIAL STRATEGY AS THE COMPANY CONTINUES ITS GLOBAL EXPANSIONAND COMMERCIALIZATION MENLO PARK, CALIF. , OCT. 21, 2025 /PRNEWSWIRE/ -- ANTHEIA , THE PHARMACEUTICAL INGREDIENT MANUFACTURER TRANSFORMING ESSENTIAL MEDICINE SUPPLY CHAINS, TODAY ANNOUNCED THE APPOINTMENT OF ERIC D'ESPARBES AS CHIEF FINANCIAL OFFICER.

ANTHEIA APPOINTS ERIC D'ESPARBES AS CHIEF FINANCIAL OFFICER

WALTHAM, MASS.--(BUSINESS WIRE)--INNOVIVA SPECIALTY THERAPEUTICS, A SUBSIDIARY OF INNOVIVA, INC. (NASDAQ: INVA), WILL SHARE NEW DATA ON ZOLIFLODACIN DURING THE INFECTIOUS DISEASE SOCIETY OF AMERICA'S IDWEEK 2025 ANNUAL MEETING IN ATLANTA, GA, OCTOBER 19-22, 2025. ZOLIFLODACIN IS A FIRST-IN-CLASS ORAL ANTIBIOTIC BEING DEVELOPED FOR THE TREATMENT OF UNCOMPLICATED GONORRHEA. THREE SETS OF DATA WILL BE PRESENTED, INCLUDING AN ORAL PRESENTATION AND TWO POSTER PRESENTATIONS: POSTER PRESENTATION P-120.

INNOVIVA SPECIALTY THERAPEUTICS ANNOUNCES ORAL PRESENTATION FEATURING NEW ANALYSES FROM THE ZOLIFLODACIN PIVOTAL PHASE 3 TRIAL AT IDWEEK 2025

WALTHAM, MASS.--(BUSINESS WIRE)--INNOVIVA SPECIALTY THERAPEUTICS, A SUBSIDIARY OF INNOVIVA, INC. (NASDAQ: INVA), TODAY ANNOUNCED THAT IT WILL DELIVER DATA FROM SIX PRESENTATIONS AT IDWEEK 2025, INCLUDING CLINICAL DATA, PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) ANALYSES, AND MICROBIOLOGIC SURVEILLANCE FROM ITS GROWING PORTFOLIO OF ANTIBIOTICS AND CRITICAL CARE MEDICINES. IDWEEK WILL BE HELD IN ATLANTA, GA, FROM OCTOBER 19-22, 2025. HIGHLIGHTS INCLUDE TWO ORAL PRESENTATIONS: A SUBSET ANALYSIS FROM.

INNOVIVA SPECIALTY THERAPEUTICS TO DELIVER SIX PRESENTATIONS FROM ITS INFECTIOUS DISEASES AND CRITICAL CARE PORTFOLIO AT IDWEEK 2025

BURLINGAME, CALIF.--(BUSINESS WIRE)--INNOVIVA, INC. (NASDAQ: INVA) (INNOVIVA OR THE COMPANY), A DIVERSIFIED HOLDING COMPANY WITH A CORE ROYALTIES PORTFOLIO, A LEADING CRITICAL CARE AND INFECTIOUS DISEASE PLATFORM KNOWN AS INNOVIVA SPECIALTY THERAPEUTICS (IST), AND A PORTFOLIO OF STRATEGIC INVESTMENTS IN HEALTHCARE ASSETS, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES IN SEPTEMBER: CITI'S 2025 BIOPHARMA BACK TO SCHOOL CONFERENCE FORMAT: FIR.

INNOVIVA TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

WALTHAM, MASS.--(BUSINESS WIRE)--PRIX GALIEN AWARD 2025.

INNOVIVA SPECIALTY THERAPEUTICS' ANTIMICROBIAL THERAPIES ZEVTERA AND XACDURO NOMINATED FOR THE 2025 PRIX GALIEN USA BEST PHARMACEUTICAL PRODUCT AWARD

ENTERED INTO SECURED CREDIT AGREEMENT WITH INNOVIVA FOR $15 MILLION MATURING IN 2029 ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE PHASE 1B/2A DISARM TRIAL FOR AP-SA02 LOS ANGELES , AUG. 12, 2025 /PRNEWSWIRE/ --ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE. SECOND QUARTER 2025 AND RECENT DEVELOPMENTS: ON AUGUST 11, 2025, ENTERED INTO A SECURED CREDIT AGREEMENT WITH INNOVIVA STRATEGIC OPPORTUNITIES LLC, A WHOLLY OWNED SUBSIDIARY OF INNOVIVA, INC., ARMATA'S LARGEST SHAREHOLDER, FOR A LOAN OF $15.0 MILLION THAT WILL MATURE ON JANUARY 11, 2029 PROCEEDS FROM THE NEW FINANCING TRANSACTION WILL BE USED TO CONTINUE TO ADVANCE DEVELOPMENT OFARMATA'S LEAD STAPHYLOCOCCUS AUREUS ("S.

Innoviva, Inc.

INVA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Innoviva, Inc.

INVA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

INVA